Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Background Proton pump inhibitors are among the most widely prescribed drugs in the world, but more than half of the indications for prescription are unjustified. The misuse of this therapeutic class has heavy consequences such as additional health costs, adverse drug reactions following long-term use and gastric acid rebound when the proton pump inhibitor is discontinued. Objective The overprescription of proton pump inhibitors is therefore becoming a public health problem, which led us to evaluate their use within the Geneva University Hospitals. Setting Patients hospitalized in two divisions of the department of internal medicine of the Geneva University Hospitals on a single day. Methods This is a register-based cross-sectional study and it collected data about the prescription pattern of proton pump inhibitors by consulting the electronic records of patients included. Main outcome measure To determine if the proton pump inhibitors prescription is made according to the market authorization and the available guidelines. Results Hundred-eighty patients were included. 54% of patients were on proton pump inhibitors, 29% of whom had their treatment initiated at hospital. Of the indications for treatment, 72% were not justified and 63% of the justified indications did not have an adequate dosage. Therefore, in all patients with a proton pump inhibitor at hospital, only 11% had a justified indication with an adequate dose. Finally, 87% of known home prescriptions were renewed on admission and among them, 71% did not have a justified or possibly justified indication according to the guidelines. Conclusion Indication for treatment inside the hospital was not justified in 72% of patients and only 11% had a justified indication with an adequate dosage. Precise guidelines with evidence-based indications and adequate daily doses would help to correctly prescribe proton pump inhibitors. Moreover, patients should benefit from a thorough evaluation of their treatment.
Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol. 2000;95(11):3118–22. PubMed
Liste « Top 5 » – pierre angulaire de la campagne « Smarter Medicine » | smartermedicine.ch [Internet]. [cited 2016 Mar 23]. Available from: http://www.smartermedicine.ch/fr/liste-top-5.
Torpey N, Barker T, Ross C. Drug-induced tubulo-interstitial nephritis secondary to proton pump inhibitors: experience from a single UK renal unit. Nephrol Dial Transpl Off Publ Eur Dial Transpl Assoc Eur Ren Assoc. 2004;19(6):1441–6.
Li X-Q, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos Biol Fate Chem. 2004;32(8):821–7. PubMedCrossRefPubMedCentral
Würtz M, Grove EL, Kristensen SD, Hvas A-M. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart Br Card Soc. 2010;96(5):368–71. CrossRef
Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management| Guidance and guidelines| NICE [Internet]. [cited 2018]. https://www.nice.org.uk/guidance/cg184.
Waldum HL, Sandvik AK, Syversen U, Brenna E. The enterochromaffin-like (ECL) cell. Physiological and pathophysiological role. Acta Oncol Stockh Swed. 1993;32(2):141–7. CrossRef
- Snapshot of proton pump inhibitors prescriptions in a tertiary care hospital in Switzerland: less is more?
Myriam El Biali
Jules Alexandre Desmeules
- Springer International Publishing
International Journal of Clinical Pharmacy
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II